Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli

By C. Giske, D. Monnet, O. Cars, Yehuda Carmeli. Antimicrobial Agents and Chemotherapy, 2007

598 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. (2009, background): “Patients at risk include those in intensive care units, particularly if they are ventilator dependent, and individuals with cystic ﬁbrosis [1, 27, 60].”
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria (2012, background): “The available evidence shows that the proportion of Gram-negative organisms resistant to commonly used antibiotics is increasing (97, 184, 192, 202).”
Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance (2017, background): “Moreover, infections caused by these strains are often associated with high mortality rates, prolonged hospitalization and costs (Giske et al. 2008).”
Hospital Epidemiology and Infection Control in Acute-Care Settings (2011, background): “ESBLs inactivate broad-spectrum cephalosporins and beta-lactamases, and they are associated with beta-lactam resistance and frequent resistance to fluoroquinolones, aminoglycosides, and trimethoprim-sulfamethoxazole (112, 231).”